Peptides Or Polypeptides, Or Derivatives Thereof Patents (Class 506/18)
  • Patent number: 11124577
    Abstract: The invention relates to a bispecific antibody specifically binding to human B cell maturation antigen (BCMA) and to human CD3? (CD3) together with an immunotherapeutic drug for combined use in treating multiple myeloma.
    Type: Grant
    Filed: November 2, 2017
    Date of Patent: September 21, 2021
    Assignee: ENGMAB SÀRL
    Inventors: Minh Diem Vu, Klaus Strein, Bruno David Lourenco Paiva, Jesus Fernado San Miguel Izquierdo
  • Patent number: 11103167
    Abstract: Presented are systems and methods that perform noninvasive glucose monitoring using mid-infrared self-emission of the human body that acts as a background radiation emitter. Various embodiments accomplish this by taking advantage of the guided-mode resonance (GMR) effect in a number of bandpass filters that are constructed as an array of coplanar filters. The filter array acts as a spectral separator that uses a grating layer and a thin film waveguide to form reflection and transmission filters for particular wavelengths. Unlike, common multi-layer optical filter designs that utilize numerous individual optical filters, a novel GMR filter design comprises an array of filters that may be fabricated from CMOS-compatible materials using only a few thin film and grating layers to filter light. Advantageously, this reduces manufacturing cost and allows for simultaneous monitoring of a number of wavelengths of the glucose spectrum.
    Type: Grant
    Filed: February 6, 2018
    Date of Patent: August 31, 2021
    Inventors: Yen-Chun Yeh, Sheng Yang, Dominik J. Schmidt
  • Patent number: 11085038
    Abstract: The invention relates to novel polypeptide libraries that are conformationally constrained in an anti-parallel, helix-turn-helix arrangement. The invention further relates to methods of generating and screening such libraries for biological, pharmaceutical and other uses.
    Type: Grant
    Filed: April 8, 2020
    Date of Patent: August 10, 2021
    Assignee: MORPHOSYS AG
    Inventors: Roger Müller, Andreas Bültmann, Josef Prassler, Markus Moosmeier
  • Patent number: 10995133
    Abstract: Disclosed is an antibody in which the 80th amino acid residue in a variable region based on the Kabat method and the 171th amino acid residue in a constant region based on the Kabat method are substituted with cysteine in an antibody in which the 80th amino acid residue in the variable region and the 171th amino acid residue in the constant region are not cysteine.
    Type: Grant
    Filed: August 2, 2018
    Date of Patent: May 4, 2021
    Assignee: SYSMEX CORPORATION
    Inventors: Nobuyuki Ide, Tomofumi Nakada
  • Patent number: 10919937
    Abstract: The present invention provides compounds, compositions thereof, and methods of using the same.
    Type: Grant
    Filed: October 23, 2019
    Date of Patent: February 16, 2021
    Assignee: BicycleTx Limited
    Inventors: Paul Beswick, Gemma Elizabeth Mudd, Kevin McDonnell, Gabriela Ivanova-Berndt, Katerine Van Rietschoten, David Witty, Michael Skynner
  • Patent number: 10899798
    Abstract: The present invention provides compounds, compositions thereof, and methods of using the same.
    Type: Grant
    Filed: June 26, 2018
    Date of Patent: January 26, 2021
    Assignee: BicycleRD Limited
    Inventors: Gavin Bennett, Daniel Paul Teufel
  • Patent number: 10802019
    Abstract: The invention relates to methods of determining whether or not an individual has or is likely to develop a neurological disease and related methods and kits.
    Type: Grant
    Filed: May 12, 2015
    Date of Patent: October 13, 2020
    Assignee: Oxford University Innovation Limited
    Inventors: Angela Vincent, Philippa Pettingill, Patrick Waters
  • Patent number: 10655125
    Abstract: The invention relates to novel polypeptide libraries that are conformationally constrained in an anti-parallel, helix-turn-helix arrangement. The invention further relates to methods of generating and screening such libraries for biological, pharmaceutical and other uses.
    Type: Grant
    Filed: March 3, 2017
    Date of Patent: May 19, 2020
    Assignee: MOR0059US.NP
    Inventors: Roger Müller, Andreas Bültmann, Josef Prassler, Markus Moosmeier
  • Patent number: 9664693
    Abstract: Methods and kits for characterizing liver damage in an individual are provided. The methods employ the use of immune analytes as biomarkers for detecting liver damage and predicting the likelihood that an individual suffering from liver damage will experience life-threatening liver failure. Concentration values for serum albumin and other identified immune analytes are obtained or determined from a blood sample taken from the individual. The obtained concentration values are then compared to corresponding concentrations from individuals having a healthy liver. By comparing the concentrations, an individual's likelihood of developing life-threatening liver failure and needing a liver transplant within a given time period (e.g., 6 months) can be identified.
    Type: Grant
    Filed: October 24, 2013
    Date of Patent: May 30, 2017
    Assignee: THE CHARLOTTE-MECKLENBURG HOSPITAL AUTHORITY
    Inventors: Herbert L. Bonkovsky, David Foureau, H. James Norton, Nury Steuerwald
  • Patent number: 9346892
    Abstract: An oligopeptide microarray and methods for the synthesis thereof are presented. Further presented is a microarray on a solid support comprising at least about 10,000 oligopeptide features per cm2 and preferably at least about 50,000 oligopeptide features per cm2.
    Type: Grant
    Filed: March 13, 2012
    Date of Patent: May 24, 2016
    Assignee: ROCHE NIMBLE GEN, INC.
    Inventors: Tom Albert, Todd Richmond, Matthew Rodesch, Klaus-Peter Stengele, Jochen Buehler, Markus Ott
  • Patent number: 9250233
    Abstract: Methods for detection of any antibody utilizing a standardized approach applicable to any antibody which provides highly specific assays specific for individual or multiple antibodies. The methods enable improved pharmacokinetic analysis during development and clinical use of antibody-based therapies as well as determination of diagnostic and/or prognostic factors.
    Type: Grant
    Filed: March 27, 2009
    Date of Patent: February 2, 2016
    Assignee: The Regents of the University of California
    Inventors: Thomas J. Kipps, Bradley T. Messmer, Ana B. Sanchez, Andrew C. Kummel, Manuel Ruidiaz
  • Patent number: 9175421
    Abstract: Provided is a method for determining one or more kinetic parameters of binding between a first binding member and a second binding member. The method includes adsorbing the first binding member to a surface at a plurality of microspots. The second binding member is then presented to the first binding member at each of the microspots, there being a plurality of combinations of first binding member surface density and second binding member concentration among the plurality of microspots. Data indicative of a binding reaction between the first of microspots are then obtained and analyzed so as to obtain one or more kinetic parameters of the binding between the first and second binding members. Also provided is a system for carrying out the method. A method for localizing a molecular species at microspots on a surface, and a probe array produced by the method are also provided.
    Type: Grant
    Filed: December 21, 2011
    Date of Patent: November 3, 2015
    Assignee: Bio-Rad Haifa Ltd.
    Inventors: Ariel Notcovich, Alon Herschhorn, Shai Nimri, John Barich, Ariel Lipson, Ran Boaz, Doron Lipson, Yaakov Levie
  • Patent number: 9168329
    Abstract: The present invention is directed to the design, synthesis and use of various ?-peptides exhibiting antifungal activity. The ?-peptides are relatively short in length, adopt globally amphiphilic conformations, and cause little lysis of human red blood cells at concentrations that kill Candida albicans, a common human fungal pathogen.
    Type: Grant
    Filed: September 4, 2007
    Date of Patent: October 27, 2015
    Assignee: Wisconsin Alumni Research Foundation
    Inventors: Sean P. Palecek, Samuel H. Gellman, William C. Pomerantz, Amy J. Karlsson
  • Patent number: 9114189
    Abstract: A modified or isolated composition comprising a gel. The gel includes a plurality of first polymers, each of said first polymers having first functional groups comprising a first nucleic acid sequence attached as side-chains thereto. The gel includes a plurality of second polymers, each of said second polymers having second functional groups comprising a second nucleic acid sequence attached as side-chains thereto, said first and said second functional groups forming a reversible cross-link between said first and said second polymers, wherein said cross-link comprises a plurality of hydrogen bonds between complementary base portions of said first and said second nucleic acid sequences.
    Type: Grant
    Filed: March 16, 2010
    Date of Patent: August 25, 2015
    Assignee: Alcatel Lucent
    Inventors: Allen P. Mills, Jr., Bernard Yurke
  • Publication number: 20150148254
    Abstract: The present invention provides methods and compositions for prognosing treatment outcome in DLBCL patients, diagnosing DLBCL and monitoring efficacy of DLBCL treatment.
    Type: Application
    Filed: November 29, 2014
    Publication date: May 28, 2015
    Inventors: Lisa M. Rimsza, Michael L. Leblanc, Joseph M. Unger
  • Publication number: 20150148247
    Abstract: The invention relates to tuberculosis diagnostic methods and devices that measure particular biomarker profiles in subjects and identify a subject having tuberculosis based on such profiles.
    Type: Application
    Filed: May 24, 2013
    Publication date: May 28, 2015
    Applicants: The Broad Institute, Inc., The General Hospital Corporati d/b/a Massachusetts General Hospital
    Inventors: Rushdy Ahmad, Michael Gillette, Steven A. Carr
  • Publication number: 20150148245
    Abstract: Methods for monitoring whether a subject will be sensitive or resistant to treatment with an anti-SMAD7 therapy are disclosed. The methods are based on the determining of the amount of CCR9+ FOXP3+ T cells, CCR9+ IFN-gamma+ T cells, CCR9+ IL17A+ T cells, FOXP3+ T cells, IFN-gamma+ T cells, and/or IL17A+ T cells in a sample from the subject. Measurement of T cell populations may be determined by flow cytometry, immunohistochemistry, and/or ELISA.
    Type: Application
    Filed: September 14, 2012
    Publication date: May 28, 2015
    Applicant: Nogra Pharma Limited
    Inventors: Giovanni Monteleone, Francesca Viti, Salvatore Bellinvia
  • Publication number: 20150139980
    Abstract: Polypeptide marker antigens for detecting the presence of autoantibody biomarkers associated with ovarian cancer recurrence, each of the polypeptide marker antigens binding specifically to at least one autoantibody marker. An antibody binding assay for detecting the presence of autoantibody biomarkers associated with ovarian cancer recurrence, and methods for performing the assay. Methods for determining ovarian cancer recurrence in an ovarian cancer patient. A method for isolating antibodies specific for ovarian cancer by their affinity to the polypeptide marker antigens, and antibodies isolated by that method.
    Type: Application
    Filed: May 6, 2013
    Publication date: May 21, 2015
    Inventors: Michael Tainsky, Madhumita Chatterjee, Gregory Dyson, Nancy Levin
  • Publication number: 20150141276
    Abstract: The present description relates to an in vitro method for the diagnosis of endometriosis, an in vitro method for the monitoring of endometriosis and a kit for the diagnosis of endometriosis and/or for the monitoring of endometriosis in a subject.
    Type: Application
    Filed: May 13, 2013
    Publication date: May 21, 2015
    Inventors: Pietro Giulio Signorile, Alfonso Baldi
  • Publication number: 20150141279
    Abstract: A method of diagnosing tuberculosis (TB) disease and distinguishing between active TB and latent TB infection in a subject is described herein. A sample from the subject is stimulated with at least one Mycobacterium tuberculosis (M.tb) infection phase-dependent antigen selected from Rv0081, Rv2032, Rv1737c, Rv2389c, Rv0867c, TB18.2, Rv2099c, Rv1733c, M.tb PPD, PHA and ESAT-6/CFP-10 and the presence of at least one host marker in the sample is detected, the host marker being selected from EGF, TGF-?, TNF-?, VEGF, RANTES, IL-12(p40), IL-12(p70), IL-10, IP-10, IFN-?2, fractalkine, IFN-?, IL-13, IL-1Ra, IL-3, IL-4, IL-5, MIP-1?, ENA-78, BCA-1, TARC, X6-Ckine, eotaxin, eotaxin-2, SCF, APOA-1, APOE, HPALBN, HCF, Serum amyloid protein A (SAA), C-reactive protein (CRP), serum amyloid protein P (SAP), TIMP-1, MIP-1?, IL-6, GM-CSF, IL-1?, MMP-9, MMP-2, MCP-1, TRAIL, IL-15, IL-17F, IL-22, TNF-?, MCP-2 and MCP-4. Additional host markers may also be detected in an unstimulated sample from the subject.
    Type: Application
    Filed: May 27, 2013
    Publication date: May 21, 2015
    Applicant: Stellenbosch University
    Inventors: Gerhard Walzl, Novel Njweipi Chegou, Paulin Essone Ndong
  • Publication number: 20150141266
    Abstract: Methods, compositions and arrays for non-random loading of single analyte molecules into array structures are provided. For example, methods are presented for providing a surface comprising the plurality of array regions by exposing the surface to a solution comprising polymerase enzymes where each polymerase enzyme is bound to a binding structure having several functional moieties. The functional moieties of the binding structure react with the binding elements on the array regions such that the functional moieties on the binding structure react with other available binding sites in an array region, preventing other polymerase-binding structures from loading, and resulting in a single polymerase molecule bound to each of these regions.
    Type: Application
    Filed: November 4, 2014
    Publication date: May 21, 2015
    Inventors: Stephen Turner, Benjamin Flusberg, Lei Sun
  • Publication number: 20150141260
    Abstract: This invention provides methods of using circulating diseased cells in the diagnosis, prognosis, or monitoring of diseases or conditions. The invention also provides methods of using circulating diseased cells to identify markers of diseases or conditions. This invention also provides methods for assessing the risk of developing a disease or condition, prognosing said disease, monitoring said disease progression or regression, assessing the efficacy of a treatment, or identifying a compound capable of ameliorating or treating said disease or condition.
    Type: Application
    Filed: June 14, 2013
    Publication date: May 21, 2015
    Inventor: Harry STYLLI
  • Publication number: 20150141325
    Abstract: A system, a composition, a method and a kit for identifying anti-bacterial agents are provided. The invention described herein is useful in identifying inhibitors of any bacterial stress response. Moreover, the invention can be applied to any sRNA and its target, any transcription factor and its target, and any transcription factor/sRNA pair (i.e., a transcription factor that regulates a sRNA). In particular, the present invention provides a system, a composition, a method and a kit for the identification of cyclic peptides that block the ?E pathway in Escherichia coli.
    Type: Application
    Filed: December 19, 2014
    Publication date: May 21, 2015
    Inventors: Sarah Ellen Ades, Kenneth Charles Keiler
  • Publication number: 20150133322
    Abstract: The present invention relates to biomarkers that are specifically recognized by autoantibodies present in a biological of patients with Rheumatoid Arthritis (RA). The invention provides methods and kits using these biomarkers for the diagnosis of RA, in particular for the diagnosis of early RA.
    Type: Application
    Filed: May 11, 2012
    Publication date: May 14, 2015
    Applicant: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE
    Inventors: Jean Roudier, Isabelle Auger
  • Publication number: 20150133305
    Abstract: The present invention is directed to methods, for example phage display assays, for bioengineering peptides that bind to individual distinct nucleotides. Also provided are peptides engineered by such methods. Specifically, cyclic peptides that bind individual distinct nucleotides are provided herein.
    Type: Application
    Filed: November 7, 2008
    Publication date: May 14, 2015
    Inventors: Mineo Yamakawa, Joseph V. Kosmoski, Deane C. Little
  • Publication number: 20150133342
    Abstract: The present invention relates to mass spectrometry methods employing multiple reaction monitoring (MRM) in the field of cancer therapeutics, specifically prostate cancer and melanoma.
    Type: Application
    Filed: May 3, 2013
    Publication date: May 14, 2015
    Inventors: Sun W. Tam, Ying Xu, Patrick J. Muraca
  • Publication number: 20150133308
    Abstract: The present invention relates to a method for improving a repebody protein comprising repeat modules and a nucleotide library encoding a repebody protein library for improving the repebody protein. More particularly, the present invention relates to a method for improving a repebody protein using a module evolution method of sequentially mutating repeat modules constituting the repebody protein, and a nucleotide library encoding a repebody protein library used to improve the protein. According to the module evolution method of the present invention, an improved repebody protein can be screened which has a high binding affinity and accordingly increased specificity and activity, and thus it is easy to express a repebody used as an inhibitor, a therapeutic agent, and an analysis means against a target substance.
    Type: Application
    Filed: November 11, 2014
    Publication date: May 14, 2015
    Inventors: Hak-Sung Kim, Joong-Jae Lee, Hyun-Ho Kyeong, Jung-Min Choi, Da-Eun Hwang, Hae-Kap Cheong, Hyun Jung Kim, Eun-Kyeong Jo, Chul-Su Yang, Jae-Min Yuk
  • Publication number: 20150133327
    Abstract: The present invention provides methods identifying subjects having prostate cancer (PCa) by detecting in micro-particles a pair of biomarkers. The methods disclosed can be used to distinguish subjects having PCa from those having non-malignant prostate pathologies, including benign prostatic hyperplasia. Methods for monitoring prostate cancer and assessing efficacy of prostate cancer therapies are also disclosed. Kits for detecting prostate cancer using the methods disclosed are also provided.
    Type: Application
    Filed: April 19, 2013
    Publication date: May 14, 2015
    Inventors: Hon Sing LEONG, Colleen Nicole BIGGS
  • Publication number: 20150126407
    Abstract: This invention provides high unit density arrays of microparticles and methods of assembling such arrays. The microparticles in the arrays may be functionalized with chemical or biological entities specific to a given target analyte. The high unit density arrays of this invention are formed on chips which may be combined to form multichip arrays according to the methods described herein. The chips and/or multichip arrays of this invention are useful for chemical and biological assays.
    Type: Application
    Filed: September 15, 2014
    Publication date: May 7, 2015
    Inventors: Michael Seul, Chiu Wo Chau, Hui Huang, Sukanta Banerjee, Jiacheng Yang, Ye Hong
  • Publication number: 20150126388
    Abstract: A surface enhanced Raman spectroscopy (SERS) marker conjugate is provided. The SERS marker conjugate comprises a metallic nanoparticle and an organometallic material attached to a surface of the metallic nanoparticle. A biosensor comprising a plurality of the SERS marker conjugates and a method of forming the SERS marker conjugate is also provided.
    Type: Application
    Filed: May 28, 2013
    Publication date: May 7, 2015
    Applicant: NANYANG TECHNOLOGICAL UNIVERSITY
    Inventors: Kien Voon Kong, Malini Olivo, Weng Kee Leong, Zhiyong Lam
  • Publication number: 20150126408
    Abstract: An anti-antibody reagent for use in a competitive or sandwich simplex or multiplex assay, said reagent comprising one or more labeled anti-antibodies for the primary antibodies to be determined in the assay, the reagent further comprising a corresponding unlabeled anti-antibody in an excess or near excess concentration with respect to their binding partners.
    Type: Application
    Filed: January 15, 2015
    Publication date: May 7, 2015
    Inventors: William F. Link, Renato B. Del Rosario, Randy Sweet, David L. King
  • Publication number: 20150126385
    Abstract: The present invention provides biomarker-based methods for diagnosing stroke in a patient suspected of having suffered a stroke, and also for discriminating between ischemic stroke and transient ischemic attack. Substrates comprising probes for specific combinations of biomarkers useful in the methods of the invention are also described.
    Type: Application
    Filed: December 3, 2012
    Publication date: May 7, 2015
    Applicant: RANDOX LABORATORIES LTD.
    Inventors: John Lamont, Ivan Mc Connell, Peter Fitzgerald
  • Publication number: 20150126394
    Abstract: Methods for diagnosing cancer in a subject are disclosed. The method includes detecting the level of expression of one or more cancer markers in a biological sample obtained from the subject; and comparing the level of expression of the one or more cancer markers in the biological sample to a normal level of expression of the one or more cancer markers. The one or more cancer markers comprises CXCL13 or CXCR5 or both CXCL13 and CXCR5. Also disclosed is a kit for detecting cancer or monitoring cancer progression.
    Type: Application
    Filed: November 6, 2014
    Publication date: May 7, 2015
    Inventors: James W. LILLARD, JR., Rajesh Singh, Shailesh Singh
  • Publication number: 20150126384
    Abstract: The present invention provides methods for assessing an ovarian cancer patient's survival status. Also, methods for evaluating the ovarian cancer state of a patient are described herein. These methods involve the detection, analysis, and classification of biological patterns in biological samples. The biological patterns are obtained using, for example, mass spectrometry systems and other techniques.
    Type: Application
    Filed: November 6, 2013
    Publication date: May 7, 2015
    Applicant: VERMILLION, INC.
    Inventors: Estrid Hogdall, Eric T. Fung, Jarle IB Christensen, Claus Hogdall
  • Publication number: 20150126386
    Abstract: The present invention relates to a method for the in vitro prediction of the probability of a patient developing severe dengue, based on a blood sample, which involves: a) determining the quantity of at least one marker, and b) comparing the quantity with a reference quantity obtained from a group of individuals who have been diagnosed with non-severe dengue, and if the quantity determined in step a) is greater than the reference quantity established in step b), predicting that the patient will develop severe dengue, and also to the use of predictive marker(s) and to a kit to predict the development of severe dengue.
    Type: Application
    Filed: January 23, 2013
    Publication date: May 7, 2015
    Inventor: Frédéric Bedin
  • Publication number: 20150119265
    Abstract: The subject matter of the present invention is a method for the diagnosis or prognosis, in vitro, of lung cancer, which includes a step of detecting at least one expression product of at least one HERV nucleic acid sequence, a method for use of said nucleic acid sequences, which have been isolated, as a molecular marker or molecular markers, and a kit including at least one binding partner specific for at least one of the expression products of the HERV nucleic acid sequences.
    Type: Application
    Filed: December 20, 2012
    Publication date: April 30, 2015
    Applicant: BIOMERIEUX
    Inventors: Philippe Perot, François Mallet, Cécile Montgiraud, Nathalie Mugnier
  • Publication number: 20150118224
    Abstract: Described herein are methods and kits for the detection of endothelial cell injury and/or activation and to the diagnostic of transplant antibody mediated rejection (ABMR). The invention further relates to methods and kits for diagnosing endothelial to mesenchymal transition (EndMT). In various embodiments, the methods comprise assessing expression of one, two or three biomarkers selected from Fascin1, Vimentin and Hsp47.
    Type: Application
    Filed: April 4, 2013
    Publication date: April 30, 2015
    Inventors: Yi-Chun Xu-Dubois, Eric Rondeau, Julie Peltier, Alexandre Hertig, Isabelle Brocheriou
  • Publication number: 20150118247
    Abstract: The invention relates to immunomodulation of cells and the detection and use thereof, for example, in drug screening, including methods, compositions and systems therefor, or in an aspect of healthcare, such as prognosis, diagnosis, an aspect of treatment, monitoring, and the like, and methods, compositions, and systems therefor.
    Type: Application
    Filed: October 27, 2014
    Publication date: April 30, 2015
    Inventors: Drew Hotson, Rachael Hawtin, Andy Conroy, Erwan Le Scolan
  • Publication number: 20150119272
    Abstract: The invention provides a computer-implemented method and system for predicting quantitatively whether an adjuvant or neoadjuvant chemotherapeutic treatment will be or is being successful in treating an individual suffering from cancer.
    Type: Application
    Filed: April 30, 2013
    Publication date: April 30, 2015
    Applicant: ROYAL COLLEGE OF SURGEONS IN IRELAND
    Inventors: Jochen Prehn, Andreas Lindner, Heinrich Huber
  • Publication number: 20150118155
    Abstract: The present invention provides a method of diagnosing the existence or risk of hyperthyroidism in a feline comprising measuring the level of expression of one or more biomarkers selected from the group consisting of e.g., IYD, TG, SLC5A5, NIS, TPO, TSHR, DUOX1, DUOX2 (ThOX), TGFB1, CSTD, DCN and SEPP1 and the expression products thereof, in a biological sample from the feline, wherein elevated expression of the one or more biomarkers in the sample relative to a control value for expression in a sample from a normal feline or feline population, or a baseline value from the feline, indicates the existence or risk of hyperthyroidism; a method of treating a feline so diagnosed; and compositions, reagents and kits for carrying out the specified methods.
    Type: Application
    Filed: June 14, 2012
    Publication date: April 30, 2015
    Applicant: Hill's Pet Nutrition, Inc.
    Inventors: Samer Al-Murrani, Xiangming Gao
  • Publication number: 20150119278
    Abstract: The present invention relates to biomarkers and diagnostic and prognostic methods for Alzheimer's disease and other neurodegenerative disorders. The invention also provides compositions for detecting the biomarker as well as compositions and methods useful for treating Alzheimer's disease and other neurodegenerative disorders.
    Type: Application
    Filed: October 24, 2014
    Publication date: April 30, 2015
    Inventor: Edward J. Goetzl
  • Publication number: 20150119259
    Abstract: This disclosure provides systems and methods for sequencing nucleic acids using nucleotide analogues and translocation of tags from incorporated nucleotide analogues through a nanopore. In aspects, this disclosure is related to composition, method, and system for sequencing a nucleic acid using tag molecules and detection of translocation through a nanopore of tags released from incorporation of the molecule.
    Type: Application
    Filed: April 8, 2013
    Publication date: April 30, 2015
    Inventors: Jingyue Ju, Randall Davis, Roger Chen
  • Publication number: 20150118218
    Abstract: The disclosure relates to methods of detecting a neural injury biomarker in a biological sample. The method includes subjecting a biological sample to an assay disclosed that produces a measurable signal and detecting the measurable signal. The presence or absence of the measurable signal indicates the presence or absence of the neural injury biomarker in the sample, and thereby diagnosing a subject as having a neural injury. The disclosure further relates to methods of determining the state of a subject's neural injury. Further disclosed are systems and devices useful in carrying out the methods disclosed.
    Type: Application
    Filed: June 11, 2012
    Publication date: April 30, 2015
    Applicant: CORNELL UNIVERSITY
    Inventors: Alexander J.A. Travis, Roy Cohen
  • Publication number: 20150118248
    Abstract: The application describes a method of screening for breast cancer by testing fro the amount of HAGE (Helicase antigen) in a sample of breast tissue. Methods of prognosis of samples of breast cancer tumours are also provided. HAGE+ ER? (estrogen receptor-) cancers are indicated as being amenable to chemotherapy. Methods of treating breast cancers with HAGE-specific CTA antigen or HAGE-specific antibodies are also provided.
    Type: Application
    Filed: March 27, 2013
    Publication date: April 30, 2015
    Inventors: Adam Linley, Morgan Mathieu, Stephanie Mcardle, Chungui Lu, Robert Rees
  • Publication number: 20150119288
    Abstract: As disclosed herein, the present invention provides for kits and a composition for diagnosis, prognosis, drug discovery, drug development, and patient stratification. The kits can comprise a plurality of binding elements for cell surface markers, and a plurality of binding elements for state-specific intracellular markers. The kits can further comprise a plurality of modulators directed for the particular cell function or signaling pathways. The kits can further include fixatives, permeabilizing agent, buffers, containers, instructions, and software for data analysis/compilation.
    Type: Application
    Filed: August 4, 2014
    Publication date: April 30, 2015
    Inventors: David M. Soper, David B. Rosen, Todd M. Covey, Ying-Wen Huang, Wendy J. Fantl, Ralph Lin
  • Publication number: 20150118199
    Abstract: Autologous bone marrow cells (BMC) are transplanted to a heterologous site in a patient after a sample of the patient's BMC has been tested and found to have a phenotypic profile which meets minimum criteria for transplantation. The phenotypic profile may be obtained by screening a sample of bone marrow cells (BMC) from the patient for the phenotypic profile, such as a CD profile, the phenotype profile may be assessed to determine the likelihood that the BMC will be suitable for transplantation to the heterologous tissue site without enriching particular phenotypic population(s) of the BMC.
    Type: Application
    Filed: October 28, 2014
    Publication date: April 30, 2015
    Inventors: Peter Altman, Cheryl Wong Po Foo
  • Publication number: 20150119263
    Abstract: Disclosed are devices that comprise a protein, such as an antibody, placed into electronic communication with a semiconductor material, such as a carbon nanotube. The devices are useful in assessing the presence or concentration of analytes contacted to the devices, including the presence of markers for prostate cancer and Lyme disease.
    Type: Application
    Filed: August 30, 2012
    Publication date: April 30, 2015
    Applicants: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA, FOX CHASE CANCER CENTER
    Inventors: Alan T. Johnson, JR., Mitchell Lerner, Matthew K. Robinson, Tatiana Pazina, Dustin Brisson, Jennifer Dailey
  • Publication number: 20150119284
    Abstract: Disclosed is a microcapsule encoded depending on the kind of a target substance included therein. The encoded microcapsule has a hydrophilic liquid core including the target substance and a hydrophobic shell surrounding the liquid core. The encoded microcapsule includes graphical codes introduced on the surface of the shell.
    Type: Application
    Filed: October 28, 2013
    Publication date: April 30, 2015
    Applicant: SNU R&DB FOUNDATION
    Inventors: Sunghoon KWON, Younghoon SONG, Taehong KWON, Daewon LEE, Junhoi KIM
  • Publication number: 20150119266
    Abstract: This invention relates to an antibody array for the analysis of the three-dimensional structure of a protein. It includes the development and production of the antibody array and methods of using the array to analyze the three-dimensional structure of a protein as well as to compare the three-dimensional structure of two proteins, for example, a therapeutic protein and a biosimilar, to determine if the two proteins are similar.
    Type: Application
    Filed: March 12, 2013
    Publication date: April 30, 2015
    Inventor: Xing Wang
  • Publication number: 20150110818
    Abstract: The invention relates to the use of an immunologically reactive microbial transglutaminase or its immunologically reactive parts or analogues, which are present in a complex with gliadin or its immunologically reactive parts or analogues, for the diagnosis and/or therapy control of coeliac disease or sprue as well as gluten sensitivity, and a kit for determining the diagnosis and/or therapy control of coeliac disease or sprue as well as of gluten sensitivity, by means of the previously mentioned complex.
    Type: Application
    Filed: April 17, 2013
    Publication date: April 23, 2015
    Inventors: Torsten Matthias, Sasha Pfeiffer, Kai Prager, Christian Meesters, Patricia Jeremias